This white paper takes a hard look at the clinical and operational limitations of sliding scale insulin; particularly as hospitals transition into mandatory CMS eCQM reporting on severe hypoglycemia and hyperglycemia beginning January 2026. You’ll learn:

• Why sliding scale remains a reactive approach that contributes to variability, adverse outcomes, and workflow inefficiencies.
• How CMS evaluates risk through outcomes reporting, not intent, and how sliding scale protocols can jeopardize performance.
• Evidence-based alternatives and readiness strategies that hospitals are successfully adopting today.